Turnstone Biologics (TSBX) Competitors $0.36 0.00 (0.00%) As of 08/11/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSBX vs. SNYR, AKTX, MURA, JATT, ENLV, ASBP, DYAI, TRIB, KZR, and MIRAShould you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Synergy CHC (SNYR), Akari Therapeutics (AKTX), Mural Oncology (MURA), JATT Acquisition (JATT), Enlivex Therapeutics (ENLV), Aspire Biopharma (ASBP), Dyadic International (DYAI), Trinity Biotech (TRIB), Kezar Life Sciences (KZR), and MIRA Pharmaceuticals (MIRA). These companies are all part of the "pharmaceutical products" industry. Turnstone Biologics vs. Its Competitors Synergy CHC Akari Therapeutics Mural Oncology JATT Acquisition Enlivex Therapeutics Aspire Biopharma Dyadic International Trinity Biotech Kezar Life Sciences MIRA Pharmaceuticals Synergy CHC (NASDAQ:SNYR) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation. Do analysts prefer SNYR or TSBX? Synergy CHC currently has a consensus price target of $10.00, indicating a potential upside of 318.41%. Turnstone Biologics has a consensus price target of $0.45, indicating a potential upside of 26.76%. Given Synergy CHC's stronger consensus rating and higher possible upside, equities research analysts clearly believe Synergy CHC is more favorable than Turnstone Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Which has stronger earnings and valuation, SNYR or TSBX? Synergy CHC has higher revenue and earnings than Turnstone Biologics. Turnstone Biologics is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC$34.83M0.65$2.12M$0.386.29Turnstone Biologics$19.31M0.43-$70.84M-$2.05-0.17 Is SNYR or TSBX more profitable? Synergy CHC has a net margin of 10.02% compared to Turnstone Biologics' net margin of 0.00%. Synergy CHC's return on equity of -18.56% beat Turnstone Biologics' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC10.02% -18.56% 20.28% Turnstone Biologics N/A -171.86%-128.13% Do insiders & institutionals believe in SNYR or TSBX? 52.5% of Turnstone Biologics shares are owned by institutional investors. 56.6% of Synergy CHC shares are owned by insiders. Comparatively, 32.1% of Turnstone Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media refer more to SNYR or TSBX? In the previous week, Synergy CHC had 9 more articles in the media than Turnstone Biologics. MarketBeat recorded 9 mentions for Synergy CHC and 0 mentions for Turnstone Biologics. Synergy CHC's average media sentiment score of 0.51 beat Turnstone Biologics' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media. Company Overall Sentiment Synergy CHC Positive Turnstone Biologics Neutral SummarySynergy CHC beats Turnstone Biologics on 15 of the 16 factors compared between the two stocks. Get Turnstone Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSBX vs. The Competition Export to ExcelMetricTurnstone BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.22M$3.07B$5.75B$9.74BDividend YieldN/A2.26%3.95%4.03%P/E Ratio-0.1721.0631.3826.41Price / Sales0.43353.19428.94154.89Price / CashN/A44.7137.7559.42Price / Book0.558.0410.446.58Net Income-$70.84M-$53.98M$3.27B$265.92M7 Day PerformanceN/A-1.02%1.04%0.13%1 Month Performance0.14%5.50%5.72%2.07%1 Year Performance-48.85%9.31%49.36%21.31% Turnstone Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSBXTurnstone Biologics3.1042 of 5 stars$0.36flat$0.45+26.8%N/A$8.22M$19.31M-0.1782SNYRSynergy CHC4.3746 of 5 stars$3.28-5.7%$10.00+204.9%N/A$32.86M$34.83M8.6340AKTXAkari Therapeutics3.3581 of 5 stars$0.99-0.9%$5.00+404.3%-78.8%$32.18MN/A0.009Positive NewsMURAMural Oncology2.7689 of 5 stars$1.80-1.1%$12.00+566.7%-34.3%$31.53MN/A-0.21119JATTJATT AcquisitionN/A$1.74+4.8%N/A-52.3%$30.02MN/A0.003High Trading VolumeENLVEnlivex Therapeutics3.2457 of 5 stars$1.05-16.0%$10.00+852.4%-17.5%$29.56MN/A-1.5970Gap UpHigh Trading VolumeASBPAspire BiopharmaN/A$0.47-20.9%N/AN/A$29.22MN/A0.00N/APositive NewsGap UpDYAIDyadic International3.4133 of 5 stars$0.79-0.6%$6.00+659.3%-33.3%$28.77M$3.49M-4.167Positive NewsTRIBTrinity Biotech1.3245 of 5 stars$1.37-12.7%N/A-85.8%$28.34M$61.56M-0.47480Upcoming EarningsGap DownKZRKezar Life Sciences3.8592 of 5 stars$3.88+0.5%$9.00+132.0%-35.4%$28.27M$7M-0.4060News CoverageMIRAMIRA Pharmaceuticals3.0968 of 5 stars$1.42-4.1%$17.00+1,097.2%-18.6%$28.22MN/A-2.902 Related Companies and Tools Related Companies Synergy CHC Competitors Akari Therapeutics Competitors Mural Oncology Competitors JATT Acquisition Competitors Enlivex Therapeutics Competitors Aspire Biopharma Competitors Dyadic International Competitors Trinity Biotech Competitors Kezar Life Sciences Competitors MIRA Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSBX) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access